CL2016002835A1 - “compuestos derivados de pladienolida con un resto piridinico; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct - Google Patents

“compuestos derivados de pladienolida con un resto piridinico; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct

Info

Publication number
CL2016002835A1
CL2016002835A1 CL2016002835A CL2016002835A CL2016002835A1 CL 2016002835 A1 CL2016002835 A1 CL 2016002835A1 CL 2016002835 A CL2016002835 A CL 2016002835A CL 2016002835 A CL2016002835 A CL 2016002835A CL 2016002835 A1 CL2016002835 A1 CL 2016002835A1
Authority
CL
Chile
Prior art keywords
pladienolide
pyridinic
pharmaceutical composition
moiety
pct
Prior art date
Application number
CL2016002835A
Other languages
English (en)
Inventor
Gregg F Keaney
John Wang
Baudouin Gerard
Kenzo Arai
Xiang Liu
Guo Zhu Zheng
Kazunobu Kira
Parcharee Tivitmahaisoon
Sudeep Prajapati
Nicholas C Gearhart
Yoshihiko Kotake
Satoshi Nagao
Sonobe Regina Kanada
Masayuki Miyano
Norio Murai
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53284528&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016002835(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of CL2016002835A1 publication Critical patent/CL2016002835A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)

Abstract

LA SOLICITUD SE REFIERE A COMPUESTOS DERIVADOS DE PLADIENOLIDA CON UN RESTO PIRIDINICO, A UNA COMPOSICIÓN FARMACÉUTICA QUE LOS COMPRENDE Y A SU USO EN EL TRATAMIENTO DEL CÁNCER.
CL2016002835A 2014-05-15 2016-11-08 “compuestos derivados de pladienolida con un resto piridinico; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct CL2016002835A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461993423P 2014-05-15 2014-05-15

Publications (1)

Publication Number Publication Date
CL2016002835A1 true CL2016002835A1 (es) 2017-04-17

Family

ID=53284528

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016002835A CL2016002835A1 (es) 2014-05-15 2016-11-08 “compuestos derivados de pladienolida con un resto piridinico; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct

Country Status (36)

Country Link
US (1) US9481669B2 (es)
EP (2) EP3514154B1 (es)
JP (1) JP6067943B1 (es)
KR (2) KR101710318B1 (es)
CN (1) CN107074827B (es)
AR (1) AR100431A1 (es)
AU (1) AU2015259237B2 (es)
BR (1) BR112016026638B1 (es)
CA (1) CA2947754C (es)
CL (1) CL2016002835A1 (es)
CY (1) CY1121550T1 (es)
DK (1) DK3143016T3 (es)
ES (1) ES2712401T3 (es)
HR (1) HRP20190432T1 (es)
HU (1) HUE041838T2 (es)
IL (1) IL248529B (es)
JO (1) JO3668B1 (es)
LT (1) LT3143016T (es)
MA (1) MA39915B1 (es)
ME (1) ME03417B (es)
MX (2) MX373324B (es)
MY (1) MY195081A (es)
PE (1) PE20170384A1 (es)
PH (1) PH12016502249B1 (es)
PL (1) PL3143016T3 (es)
PT (1) PT3143016T (es)
RS (1) RS58400B1 (es)
RU (1) RU2707730C2 (es)
SG (1) SG11201609693XA (es)
SI (1) SI3143016T1 (es)
SM (1) SMT201900158T1 (es)
TR (1) TR201902328T4 (es)
TW (1) TWI634115B (es)
UA (1) UA119458C2 (es)
WO (1) WO2015175594A1 (es)
ZA (1) ZA201607354B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2887201T3 (es) 2015-09-01 2021-12-22 Eisai R&D Man Co Ltd Variantes de empalme asociadas con mutantes neomórficos de SF3B1
SG11201803519YA (en) * 2015-11-18 2018-06-28 Eisai R&D Man Co Ltd A solid state form of pladienolide pyridine compounds and methods of use
SG11201907887SA (en) 2017-03-15 2019-09-27 Eisai Co Ltd Spliceosome mutations and uses thereof
SG11202003197TA (en) 2017-10-31 2020-05-28 Eisai R&D Man Co Ltd Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from bcl2 inhibitors, bcl2/bclxl inhibitors, and bclxl inhibitors and methods of use
WO2019199667A2 (en) * 2018-04-09 2019-10-17 Keaney Gregg F Certain pladienolide compounds and methods of use
PE20212329A1 (es) * 2018-04-12 2021-12-14 Eisai Randd Man Co Ltd Derivados de pladeniolida como agentes dirigidos a empalmosoma para tratar el cancer
MX2020012940A (es) * 2018-06-01 2021-03-25 Eisai R&D Man Co Ltd Metodos de uso de moduladores de empalme.
JOP20200268A1 (ar) 2018-06-01 2020-10-26 Eisai R&D Man Co Ltd تضفير مترافقات عقار جسم مضاد معدل وطرق استخدامها
IL262658A (en) * 2018-10-28 2020-04-30 Memorial Sloan Kettering Cancer Center Prevention of age related clonal hematopoiesis and diseases associated therewith
AR122546A1 (es) * 2020-06-05 2022-09-21 Eisai R&D Man Co Ltd Conjugados de anticuerpo anti bcma-fármaco y métodos de uso
KR20230104204A (ko) 2020-11-04 2023-07-07 에자이 알앤드디 매니지먼트 가부시키가이샤 골수이형성 증후군(mds)에 대한 바이오마커 및 이를 사용하는 방법
EP4361136A4 (en) * 2021-06-18 2025-08-13 Univ Cordoba Compound for the treatment of glioblastoma
CN113876771B (zh) * 2021-11-12 2022-09-23 中国医学科学院基础医学研究所 一种靶向pabpc1的小分子药物及其在慢性髓系白血病中的应用
WO2023131866A1 (en) 2022-01-05 2023-07-13 Eisai R&D Management Co., Ltd. Biomarkers for myelodysplastic syndrome (mds) and methods of using the same
MA71743A (fr) 2022-11-07 2025-05-30 Eisai R&D Management Co., Ltd. Procédé de production d'un composé macrolide

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI311558B (en) 2001-02-01 2009-07-01 Mercian Corporatio Novel physiologically active substance
TWI334866B (en) 2002-05-29 2010-12-21 Mercian Corp Novel physiologically active substances
RU2338741C2 (ru) 2002-07-31 2008-11-20 Мершан Корпорейшн Новые физиологически активные вещества
JP4459051B2 (ja) 2002-07-31 2010-04-28 メルシャン株式会社 新規生理活性物質
WO2004037212A2 (en) 2002-10-24 2004-05-06 Sepracor, Inc. Compositions comprising zopiclone derivatives and methods of making and using the same
JP4439401B2 (ja) 2002-11-29 2010-03-24 メルシャン株式会社 マクロライド系化合物の製造方法
EP1705247A4 (en) 2003-11-27 2008-08-20 Mercian Corp DNA ACCOMPANYING HYDROXYLATION OF A MAKROLIDE COMPOUND
ES2345493T3 (es) 2003-11-28 2010-09-24 Kanagawa Academy Of Science And Technology Metodo de deteccion de cancer de higado, diagnostico de cancer de higado y remedio para el cancer.
US20070199741A1 (en) 2004-07-02 2007-08-30 Kenji Noumi Combined Weighing Apparatus
CN1977046A (zh) 2004-07-20 2007-06-06 卫材R&D管理有限公司 编码参与普拉地内酯生物合成的多肽的dna
TW200716744A (en) * 2005-05-26 2007-05-01 Eisai R&D Man Co Ltd Genetically modified microorganism and process for production of macrolide compound using the microorganism
CN101282967B (zh) 2005-10-13 2011-01-26 卫材R&D管理有限公司 普拉二烯内酯b和普拉二烯内酯d的全合成
WO2008111464A1 (ja) * 2007-03-05 2008-09-18 Eisai R & D Management Co., Ltd. スプライシング異常を指標とする抗ガン剤の作用検定方法
US20080312317A1 (en) 2007-04-12 2008-12-18 Eisai R&D Management Co., Ltd. 12 membered-ring macrolactam derivatives

Also Published As

Publication number Publication date
PH12016502249B1 (en) 2023-12-13
SI3143016T1 (sl) 2019-04-30
CN107074827A (zh) 2017-08-18
EP3514154B1 (en) 2022-08-03
JO3668B1 (ar) 2020-08-27
JP2017505282A (ja) 2017-02-16
US9481669B2 (en) 2016-11-01
ME03417B (me) 2020-01-20
EP3514154A1 (en) 2019-07-24
JP6067943B1 (ja) 2017-01-25
IL248529B (en) 2019-11-28
ZA201607354B (en) 2018-05-30
BR112016026638B1 (pt) 2022-08-02
SMT201900158T1 (it) 2019-05-10
CA2947754A1 (en) 2015-11-19
HRP20190432T1 (hr) 2019-04-19
RU2707730C2 (ru) 2019-11-29
KR101710318B9 (ko) 2026-02-06
CY1121550T1 (el) 2020-05-29
AU2015259237A1 (en) 2016-11-10
MX2020004476A (es) 2021-12-08
PT3143016T (pt) 2019-02-27
KR20160082256A (ko) 2016-07-08
AU2015259237B2 (en) 2019-08-15
DK3143016T3 (en) 2019-04-08
KR101710318B1 (ko) 2017-02-24
PL3143016T3 (pl) 2019-04-30
TR201902328T4 (tr) 2019-03-21
RS58400B1 (sr) 2019-04-30
CA2947754C (en) 2024-01-02
HUE041838T2 (hu) 2019-05-28
PE20170384A1 (es) 2017-05-11
MX2016014997A (es) 2017-06-29
CN107074827B (zh) 2020-12-18
RU2016148887A3 (es) 2018-12-11
EP3143016A1 (en) 2017-03-22
LT3143016T (lt) 2019-06-10
SG11201609693XA (en) 2016-12-29
PH12016502249A1 (en) 2017-02-06
NZ725603A (en) 2023-11-24
MX373324B (es) 2020-05-04
NZ764190A (en) 2023-11-24
BR112016026638A2 (es) 2017-08-15
IL248529A0 (en) 2016-12-29
RU2019124012A (ru) 2019-08-12
MA39915B1 (fr) 2019-05-31
US20150329528A1 (en) 2015-11-19
TW201625596A (zh) 2016-07-16
KR102146726B9 (ko) 2026-02-05
EP3143016B1 (en) 2018-12-12
KR20170021899A (ko) 2017-02-28
ES2712401T3 (es) 2019-05-13
UA119458C2 (uk) 2019-06-25
RU2016148887A (ru) 2018-06-18
MX388580B (es) 2025-03-20
MY195081A (en) 2023-01-09
AR100431A1 (es) 2016-10-05
WO2015175594A1 (en) 2015-11-19
TWI634115B (zh) 2018-09-01
MA39915A (fr) 2017-03-22
KR102146726B1 (ko) 2020-08-21

Similar Documents

Publication Publication Date Title
CL2016002835A1 (es) “compuestos derivados de pladienolida con un resto piridinico; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
CL2023001910A1 (es) Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo
CL2016002516A1 (es) “compuestos derivados de espirociclo sustituidos, inhibidores atx; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, inflamaciones, dolor neuropático, enfermedades fibróticas, trombosis, entre otros”. pct
CL2016001933A1 (es) Compuestos derivados de macrociclos, inhibidores del factor xia composición farmacéutica que los comprende y su uso en el tratamiento yo profilaxis de una enfermedad tromboembolica. pct
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
CO2017001994A2 (es) Compuestos activos hacia bromodominios
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
CL2013002898A1 (es) Compuestos derivados de benceno sustituido con arilo o heteroarilo; composicion farmaceutica que los comprende y uso en el tratamiento del cancer.
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CL2016003398A1 (es) Compuestos de heteroarilo útiles como inhibidores de enzima activadora de sumo.
CL2016001120A1 (es) Compuestos derivados de pirrolo1,2-f1,2,4triazina ,composición farmacéutica que los comprende y su uso en el tratamiento de una infección por virus sincicial compuestos intermediarios. pct
CL2015003280A1 (es) Derivados de benzimidazol como inhibidores de bromodominio
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
CL2016000783A1 (es) “compuestos derivados de isoquinolinona y quinazolinona, inhibidores pi3k; composición farmacéutica que los comprende; útiles en el tratamiento del cáncer, enfermedades inflamatorias y autoinmune”. pct
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2016000381A1 (es) Compuestos antivirales
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
CR20160425A (es) Moléculas de anticuerpos que se unen a lag-3 y usos de las mismas
BR112015019432A2 (pt) Compostos de tubulisina, métodos de produção e uso
CL2016003092A1 (es) “compuestos derivados de pirazol sustituido, bloqueadores de canales de calcio tipo t; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, enfermedades del snc, cardiovasculares, neuropatía diabética, infertilidad y disfunción sexual”. pct
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
DOP2016000336A (es) Derivados de isoindolina para uso en el tratamiento de una infeccion viral
CL2015002897A1 (es) Inhibidores de bace1